27 December 2018

Due Diligence for a Novel Software Used in Clinical Trials

Written by Colin G. Miller



An investment company was considering a major investment in a company with a novel system for evaluating risk-based monitoring (RBM) in clinical trials.  They needed an expert in clinical trials and due diligence to evaluate the software and work with the financial team to ensure the product had a significant potential market.  With the latest guidelines ICH E6 (R2) the software had to compete in a newly developing area.


A complete due diligence report was written in eight weeks that included the following:

  • Software evaluation

  • Market potential evaluation, examining the regulatory framework and competitive landscape

  • Interviews of current customers (x6 to gain clear insight into the pros and cons)

  • A marketing survey to gain an understanding of the competitive landscape and the client’s name recognition

  • Interviews of the CEO and other key staff

  • SWOT analysis

  • Work with the financial team, who were running Monte Carlo simulations to predict breakeven and time to profit

  • Recommendations for a business plan and next steps in gaining market penetration


Based on the analysis provided the investment group made a confident investment in the software company.



Supporting Biotech and Pharma Companies Using Imaging Endpoints in Clinical Trials

The use of imaging endpoints in clinical trials has steadily increased over the last 30 years...

Navigating Critical Regulatory Requirements in Alignment with Sponsors' Unique Challenges and Goals

Careful, timely, and strategic navigation of regulatory requirements is essential for sponsors who..